Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $9.00 at Oppenheimer
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its target price cut by Oppenheimer from $10.00 to $9.00 in a report released on Wednesday,Benzinga reports. They currently have an outperform rating on the stock. ALLO has been the topic of a number of other research reports. Citizens Jmp cut shares of Allogene Therapeutics from an “outperform” […]
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its target price cut by Oppenheimer from $10.00 to $9.00 in a report released on Wednesday,Benzinga reports. They currently have an outperform rating on the stock. ALLO has been the topic of a number of other research reports. Citizens Jmp cut shares of Allogene Therapeutics from an “outperform” […]
